2022/23 Publications

Between 1st April 2022 - 31st March 2023, the following articles were published by researchers using the NIHR Sheffield Clinical Research Facility (CRF).

Accident & Emergency


Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes (STH15908: PEGASUS)

Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial (STH15908: PEGASUS)

Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54 (STH15908: PEGASUS)

Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction. Results From the COMPLETE Randomized Clinical Trial (STH18050: COMPLETE)

TCT-36 Complete Revascularization Versus Culprit Lesion–Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial (STH18050: COMPLETE)

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial (STH19388: IRONMAN)

Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial (STH19671: RIPCORD2)

Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial (STH19837: LIBERATES)

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry (STH21180: NSTEMI Registry)

Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology (STH21180: NSTEMI Registry)

Clinical Immunology

Critical Care, Anaesthesia & Operating Services

Diabetes & Endocrinology



Infectious Diseases

Clonal population expansion of Staphylococcus aureus occurs due to escape from a finite number of intraphagocyte niches (STH14625: Macrophage responses to micro-organisms)

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country (STH20140: DEN 314)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (STH21355: RECOVERY)

Factors affecting turnaround time of SARS-CoV-2 sequencing for inpatient infection prevention and control decision making: analysis of data from the COG-UK HOCI study (STH21374: COG-UK HOCI)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females (STH21413: COV002)

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study (STH21439: PHOSP-COVID)

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study (STH21439: PHOSP-COVID)

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination (STH21439: PHOSP-COVID)

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens (STH21520: PITCH)

A plain language summary of the Janssen COVID-19 vaccine effectiveness and safety as a single dose and with a booster (STH21570: ENSEMBLE-2)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial (STH21570: ENSEMBLE-2)

Medical Imaging & Medical Physics

Metabolic Bone



Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months (STH16508:TONIC)

Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? (STH16542: MIST)

Moderators of cognitive behavioural therapy treatment effects and predictors of outcome in the CODES randomised controlled trial for adults with dissociative seizures (STH18295: CODES)

Performance of the GAD-7 in adults with dissociative seizures (STH18295: CODES)

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (STH19145: SOD1)

Rapid identification of human muscle disease with fibre optic Raman spectroscopy (STH19266: Raman)

Key demographics and psychological skills associated with adjustment to progressive Multiple Sclerosis early in the diagnosis (STH19549: Psychological Adjustment in Progressive Multiple Sclerosis (PAIPMS))

Non-negative matrix factorisation of Raman spectra finds common patterns relating to neuromuscular disease across differing equipment configurations, preclinical models and human tissue (STH19904: Novel electrical impedance spectroscopy for neurological disorders.)

Fatigue in multiple sclerosis: A UK MS-register based study (STH19939: MS Register)

Vagus nerve stimulation paired with rehabilitation for stroke: Implantation experience from the VNS-REHAB trial (STH20221: VNS-REHAB)

Vagus Nerve Stimulation Paired With Rehabilitation for Upper Limb Motor Impairment and Function After Chronic Ischemic Stroke: Subgroup Analysis of the Randomized, Blinded, Pivotal, VNS-REHAB Device Trial (STH20221: VNS-REHAB)

RNA-Seq Profiling of Neutrophil-Derived Microvesicles in Alzheimer’s Disease Patients Identifies a miRNA Signature That May Impact Blood–Brain Barrier Integrity (STH20325: Infection & Dementia)

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (STH20709: NOVA)


Renal Services